CN103860475A - Toltrazuril soluble powder and preparation method thereof - Google Patents
Toltrazuril soluble powder and preparation method thereof Download PDFInfo
- Publication number
- CN103860475A CN103860475A CN201210550538.0A CN201210550538A CN103860475A CN 103860475 A CN103860475 A CN 103860475A CN 201210550538 A CN201210550538 A CN 201210550538A CN 103860475 A CN103860475 A CN 103860475A
- Authority
- CN
- China
- Prior art keywords
- toltrazuril
- soluble powder
- cosolvent
- preparation
- spice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960000898 toltrazuril Drugs 0.000 title claims abstract description 43
- 239000000843 powder Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000006184 cosolvent Substances 0.000 claims abstract description 13
- 239000000945 filler Substances 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000000796 flavoring agent Substances 0.000 claims abstract description 7
- 235000019634 flavors Nutrition 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 235000013599 spices Nutrition 0.000 claims description 14
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical group OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- 241000723347 Cinnamomum Species 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 4
- 235000012141 vanillin Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000035622 drinking Effects 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 238000007689 inspection Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000012797 qualification Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 208000003495 Coccidiosis Diseases 0.000 description 9
- 206010023076 Isosporiasis Diseases 0.000 description 9
- 230000001165 anti-coccidial effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930191564 Monensin Natural products 0.000 description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960005358 monensin Drugs 0.000 description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000499566 Eimeria brunetti Species 0.000 description 2
- 241000223934 Eimeria maxima Species 0.000 description 2
- 241000223932 Eimeria tenella Species 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003250 oocyst Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000001563 schizont Anatomy 0.000 description 2
- SJUWEPZBTXEUMU-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide Chemical compound Br.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 SJUWEPZBTXEUMU-LDXVYITESA-N 0.000 description 1
- NAPNOSFRRMHNBJ-UHFFFAOYSA-N Arprinocid Chemical compound C1=NC=2C(N)=NC=NC=2N1CC1=C(F)C=CC=C1Cl NAPNOSFRRMHNBJ-UHFFFAOYSA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 1
- 241000179199 Eimeria mitis Species 0.000 description 1
- CNHITNQXNUHOKX-UHFFFAOYSA-N NC(=N)N.C1=CC=CC=C1.[O] Chemical compound NC(=N)N.C1=CC=CC=C1.[O] CNHITNQXNUHOKX-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- MCAJAYQYDGFSJO-UHFFFAOYSA-N acetonitrile benzene triazine Chemical compound C(C)#N.C1=CC=CC=C1.N1=NN=CC=C1 MCAJAYQYDGFSJO-UHFFFAOYSA-N 0.000 description 1
- 229950002343 arprinocid Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000731 clopidol Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Seasonings (AREA)
Abstract
The invention relates to toltrazuril soluble powder and a preparation method thereof, and the toltrazuril soluble powder is prepared from toltrazuril as a main material and a cosolvent, soluble filler, an essence and the like as auxiliary materials by drying, weighing, crushing, sieving, mixing, qualification inspection and packaging. The toltrazuril soluble powder product has the characteristics of being simple to use, low in cost, rich in flavor and taste, stable in storage, convenient in transportation, good in water solubility and the like, and the efficacy of the toltrazuril on animals can be greatly improved by preparation of a drinking agent.
Description
Technical field
The present invention relates to soluble powder for animals and technique thereof, particularly a kind of toltrazuril soluble powder and preparation method thereof.
Background technology
Toltrazuril belongs to triazine benzene acetonitrile platform thing, for novel, efficient, low toxicity anticoccidial drug, is widely used in chicken coccidiosis.The Toltrazuril anticoccidial mechanism of action is also not clear.To the coccidiosis Main Function peak phase, different with the different genera of coccidiosis, as the sexual cycle that has 2nd generation schizont coccidiosis to Eimeria tenella Main Function point.But to huge, E.brunetti schizont is invalid.The zygote stage to Eimeria maxima application point coccidiosis; The E.brunetti microgametophyte stage is had efficiently.Ground gram ball profit also has inhibitory action to forming Sporulated Oocysts.Show according to clinical trial, Toltrazuril is better than anticoccidial drug and the monensin plasma carrier anticoccidial drug of other conventional application to the prevention effect of coccidiosis.
Show according to clinical trial, Toltrazuril is tender to chicken, heap type, murder by poisoning, Bu Shi, Eimeria maxima effect are splendid, after medication, decapacitation is controlled outside the generation and death of caecum coccidiosis effectively, even can make disease chicken coccidial oocyst all disappear, and real is the desirable worm medicine of killing.Toltrazuril also has efficiently Eimeria mitis.Toltrazuril is also better than anticoccidial drug and the monensin plasma carrier anticoccidial drug of other conventional application to the prevention effect of coccidiosis.Also have evidence, to the Eimeria tenella of fluoropurine (Arprinocid), clopidol, halofuginone hydrobromide, oxygen benzene guanidine, monensin drug resistance, application Toltrazuril is still effective.Toltrazuril is insoluble in water, is conventionally used for preventing 2～4mg/kg to be used for the treatment of with 1mg/kg clinically, this medicine is nontoxic, noresidue, be difficult for produce drug resistance, poultry before government official without drug withdrawal.This medicine is added on and in feedstuff, prevents coccidiosis by 1mg/kg always after coming out.Mainly contain in the market the dosage forms such as Toltrazuril pre-mixing agent, suspension type powder, solution.The subject matter that this series products exists is that, after mixing with drinking water, because Toltrazuril dissolubility is extremely low, medicine generation sedimentation, causes chicken can not fully drink enough medicines; When spice uses, because the clinical using dosage of Toltrazuril is low, be difficult to mix homogeneously, certainly will affect like this anticoccidial effect.The Toltrazuril of indissoluble can be formed in to clinical use by preparation process technology time, in being dissolvable in water the state of water, make clinical use more convenient, more effective.
Summary of the invention
?the object of the invention is to overcome the deficiency of the existing dosage form of Toltrazuril, develop a kind of good water solubility, use simple, with low cost, stable storing, the animal specific toltrazuril soluble powder agent of convenient transportation.
The object of the invention is to realize in the following manner:
A kind of animal specific toltrazuril soluble powder, it is equipped with appropriate cosolvent, solubility filler, spice mainly take Toltrazuril as major ingredient, and the conventional methods such as drying, weighing, pulverizing, mixing, subpackage are prepared from.
It is characterized in that it is made up of the raw material of following percentage by weight:
Toltrazuril 0.5%-1%
Cosolvent 1%-80%
Solubility filler 0.1%-90%
Spice 0.1%-1%
Wherein, cosolvent used is malic acid.
Solubility filler used is one or more in glucose, sucrose, soluble starch etc.
Spice is cinnamon flavor, vanillin etc.
Animal specific toltrazuril soluble powder of the present invention agent has the features such as use is simple, with low cost, fragrance is various, stable storing, convenient transportation, good water solubility, is mixed with drinking agent and can greatly improves the curative effect of Toltrazuril to animal.
The specific embodiment
The present invention implements in the following manner.
One, Toltrazuril, cosolvent, solubility filler, spice are dried respectively.
Two, take respectively the above-mentioned substance of required quality.
Three, pulverize, sieve.
Four, through mixing after the assay was approved, subpackage.
Wherein, Toltrazuril consumption is 0.5%-1%, and cosolvent adopts malic acid, and consumption is 1%-80%; Solubility filler adopts one or more in glucose, sucrose, soluble starch etc., and content is 0.1%-90%, and spice is cinnamon flavor, and content is 0.1%-1%.
Spice is cinnamon flavor, vanillin etc.
Embodiment mono-
One, Toltrazuril, cosolvent, solubility filler, spice are dried respectively, make its moisture be not more than 5%.
Two, take respectively Toltrazuril 5g, malic acid 50g, glucose 944g, cinnamon flavor 1g.
Three, pulverize, cross sieve No. five.
Four, mix one hour, after the assay was approved, subpackage.
Embodiment bis-
One, Toltrazuril, cosolvent, solubility filler, spice are dried respectively, make its moisture be not more than 5%.
Two, take respectively Toltrazuril 10g, malic acid 150g, glucose 835g, cinnamon flavor 5g.
Three, pulverize, cross sieve No. five.
Four, mix one hour, after the assay was approved, subpackage.
Embodiment tri-
One, Toltrazuril, cosolvent, solubility filler, spice are dried respectively, make its moisture be not more than 5%.
Two, take respectively Toltrazuril 5g, malic acid 100g, sucrose 894g, vanillin 1g.
Three, pulverize, cross sieve No. five.
Four, mix one hour, after the assay was approved, subpackage.
Claims (3)
1. toltrazuril soluble powder and preparation method thereof, is characterized in that described toltrazuril soluble powder agent is to be made up of principal agent and adjuvant, and major ingredient comprises Toltrazuril, and adjuvant comprises cosolvent, solubility filler, spice etc.
2. toltrazuril soluble powder as claimed in claim 1, and be characterised in that cosolvent is malic acid, solubility filler is one or more in glucose, sucrose, soluble starch etc., spice is cinnamon flavor, one or more in vanillin etc.
3. toltrazuril soluble powder as claimed in claim 1, its each constituent mass content is composed as follows:
Toltrazuril 0.5%-1%
Cosolvent 1%-80%
Solubility filler 0.1%-90%
Spice 0.1%-1%
The preparation method of toltrazuril soluble powder as claimed in claim 1, its feature is as follows: Toltrazuril, cosolvent, solubility filler, spice dried respectively, weighs, pulverize, sieve, through mixing after the assay was approved, subpackage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550538.0A CN103860475A (en) | 2012-12-18 | 2012-12-18 | Toltrazuril soluble powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550538.0A CN103860475A (en) | 2012-12-18 | 2012-12-18 | Toltrazuril soluble powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103860475A true CN103860475A (en) | 2014-06-18 |
Family
ID=50899869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210550538.0A Pending CN103860475A (en) | 2012-12-18 | 2012-12-18 | Toltrazuril soluble powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103860475A (en) |
-
2012
- 2012-12-18 CN CN201210550538.0A patent/CN103860475A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102228120B (en) | Cassia seed lotus leaf coffee | |
| WO2010078023A4 (en) | Food-based supplement delivery system | |
| US20110124577A1 (en) | Preparation for oral administration comprises quercetin glycoside and a water-based solvent extract of cartilage containing chondroitin sulfate | |
| TW201519894A (en) | Composition comprising fructooligosaccharide and quercetin glycoside | |
| CN101933930B (en) | Novel compound anti-coccidiosis medicament and preparation method thereof | |
| CN102450364A (en) | Health tea for relieving alcoholism | |
| KR102098079B1 (en) | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component | |
| CN105054007A (en) | Health-care moringa seed product | |
| US20120189653A1 (en) | Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient | |
| CN104432063A (en) | Composition for alleviating athletic fatigue and preparation method thereof | |
| CN102114067B (en) | Compound oviductus ranae granules and application thereof | |
| CN103083247A (en) | Diclazuril soluble powder and preparation method thereof | |
| CN103860475A (en) | Toltrazuril soluble powder and preparation method thereof | |
| JP2016124832A (en) | Energy metabolism activator in muscle cells | |
| JP7016510B2 (en) | Blood cholesterol elevation inhibitory composition | |
| KR101355482B1 (en) | Production method of Tea using Vitamin C | |
| US20100273737A1 (en) | Supplementary food composition for reducing body odor | |
| CN103816256A (en) | Composition with physiological functions | |
| CN106361741B (en) | A kind of chlorophyll composition for being used to treat constipation | |
| CN104605150B (en) | A kind of composite vegetables extractive animal health-care product and its application | |
| CN107927245A (en) | A kind of functional solid beverage and its preparation process for improving anoxia endurance | |
| JP4688555B2 (en) | Low-density lipoprotein lowering agent in blood containing Ashitaba and chitosan or its derivatives | |
| JP2010248161A (en) | Anti-fatigue agent or physical fitness improver containing uridine | |
| US10294019B2 (en) | System for preparing medicinal beverages using cartridge-type beverage brewers | |
| JP2005239550A (en) | Fatigue prevention / recovery agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140618 |